Amyloidosis – Talk Bio

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition

8 months ago talkbio0Tagged Alnylam, Amyloidosis, ATTR-CM, Cardiomyopathies, HELIOS-B, Phase 3 trial, RNA Interference, vutrisiran

Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis

CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests

10 months ago talkbio0Tagged Amyloidosis, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Intellia, Prealbumin, re-dosing

CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing

Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran

10 months ago talkbio0Tagged Alnylam, Amyloidosis, Cardiomyopathies, RNA Interference, TTR wt Allele, vutrisiran

Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy